Clinical trials are the backbone of medical innovation, but far too often, they reinforce existing health inequities. Poor site selection, outdated assumptions, and limited visibility into real-world patient distribution lead to underrepresentation and missed opportunities.
InsightLaunch™ by UniqueMinds helps pharma teams leverage AI to synthesize patient data across geographies, demographics, and health systems, enabling faster, fairer, and more strategic trial site decisions. Built on the RAIFH™ framework, it ensures innovation doesn’t come at the cost of inclusion.
The Challenge: When Site Selection Reinforces Systemic Gaps
Many trial site strategies still rely on historical recruitment performance or physician preference. While familiar, this approach perpetuates blind spots:
- Urban academic centers are prioritized, while rural or safety-net clinics are overlooked
- Racial and ethnic minorities remain underrepresented in enrollment
- Recruitment timelines are stretched, delaying market access and scientific discovery
These aren’t just operational inefficiencies — they are structural equity failures. As regulators push for broader representation and real-world evidence becomes a competitive advantage, pharma companies can no longer afford to treat diversity as an afterthought.
But how do you surface new trial opportunities without reinventing the wheel?
The Approach: InsightLaunch™ and Multimodal Patient Data Synthesis
InsightLaunch™ enables life sciences teams to make smarter site decisions by aggregating and analyzing real-world, real-time data from multiple sources. This includes EHRs, claims data, SDOH indicators, geographic care access patterns, and even public health datasets.
In one immuno-oncology trial, a global sponsor used InsightLaunch™ to identify clusters of eligible patients in medically underserved zip codes — areas previously excluded from feasibility models. AI was used to:
- Map clinical eligibility against real-world diagnoses and referral patterns
- Layer in social determinants like transportation access and income instability
- Rank potential sites by both scientific fit and community reach
- Flag “quiet high-opportunity” clinics — such as FQHCs or smaller health systems — that could benefit from trial support infrastructure
The result? Sites that reflected the actual burden of disease, not just historical recruitment volume.
RAIFH™ in Action: Equity by Design, Not by Exception
As with all UniqueMinds solutions, InsightLaunch™ is grounded in the Responsible AI Framework for Healthcare™ (RAIFH™) — a proprietary framework that ensures AI enhances human insight, preserves trust, and promotes ethical excellence.
Here’s how RAIFH™ shaped this trial site strategy:
- Fairness & Non-Discrimination: AI flagged where trial inclusion criteria might exclude high-need populations — enabling protocol refinement before outreach began
- Fit for Use: Data inputs were validated for reliability, granularity, and context — preventing over-indexing on any one data stream (e.g., claims vs. clinical)
- Human Participation: Site selection wasn’t automated — it was augmented. Regional teams validated AI recommendations and layered in on-the-ground insight
- Transparency: Every scoring metric — from demographic parity to catchment size — was explainable and auditable
- Accountability: Cross-functional governance teams from clinical operations, DEI, and regulatory affairs collaborated to review outputs and guide implementation
This wasn’t about outsourcing decisions to AI — it was about using AI to ask better questions and surface overlooked opportunities.
The Impact: Faster Start-Up, Broader Access, Smarter Science
The trial described launched three months ahead of schedule. More than 30% of enrolled participants came from historically underrepresented groups — not because of quota-filling, but because the trial was designed to meet people where they are.
Regional investigators gained access to new support resources. Community-based providers were included in scientific dialogue. And the sponsor’s regulatory and commercial teams were better positioned to make future access claims grounded in diverse, real-world representation.
All of this began not with a protocol tweak, but with a reimagining of site strategy — guided by InsightLaunch™.
Broader Insight: Why This Moment Matters for Pharma
The industry is at a crossroads. Regulators are requiring more representation. Payers are demanding real-world value. Patients are demanding trust.
Site selection is no longer just a logistical step — it’s a signal of intent. Of who gets included in innovation. Of where pharma places its bets — and whom it decides to serve.
With InsightLaunch™, AI becomes a bridge — connecting trial design to real-world equity. And with RAIFH™ at the core, organizations don’t just move fast — they move responsibly.
UniqueMinds sets the standard for Responsible Intelligence™ in life sciences — helping pharma make smarter decisions that reflect the future of care.
Reimagine Your Trial Strategy With Insight
If your clinical development team is designing for speed, scale, or inclusion — ask yourself:
“Are we building on data — or just relying on precedent?”
Partner with UniqueMinds to see how InsightLaunch™ can help you unlock smarter, fairer site strategies that align scientific ambition with patient reality.
